109 related articles for article (PubMed ID: 14515196)
1. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy.
Behrendt CE; Ruiz RB
Thromb Haemost; 2003 Oct; 90(4):734-7. PubMed ID: 14515196
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
Bissett D; O'Byrne KJ; von Pawel J; Gatzemeier U; Price A; Nicolson M; Mercier R; Mazabel E; Penning C; Zhang MH; Collier MA; Shepherd FA
J Clin Oncol; 2005 Feb; 23(4):842-9. PubMed ID: 15681529
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
Douillard JY; Peschel C; Shepherd F; Paz-Ares L; Arnold A; Davis M; Tonato M; Smylie M; Tu D; Voi M; Humphrey J; Ottaway J; Young K; Vreckem AV; Seymour L
Lung Cancer; 2004 Dec; 46(3):361-8. PubMed ID: 15541822
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
7. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
Heath EI; Burtness BA; Kleinberg L; Salem RR; Yang SC; Heitmiller RF; Canto MI; Knisely JP; Topazian M; Montgomery E; Tsottles N; Pithavala Y; Rohmiller B; Collier M; Forastiere AA
Invest New Drugs; 2006 Mar; 24(2):135-40. PubMed ID: 16502351
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
11. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
12. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM
Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Mellema WW; van der Hoek D; Postmus PE; Smit EF
Lung Cancer; 2014 Oct; 86(1):73-7. PubMed ID: 25129368
[TBL] [Abstract][Full Text] [Related]
17. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model.
Liu J; Tsao MS; Pagura M; Shalinsky DR; Khoka R; Fata J; Johnston MR
Lung Cancer; 2003 Dec; 42(3):335-44. PubMed ID: 14644522
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
Haas SK; Freund M; Heigener D; Heilmann L; Kemkes-Matthes B; von Tempelhoff GF; Melzer N; Kakkar AK;
Clin Appl Thromb Hemost; 2012; 18(2):159-65. PubMed ID: 22275397
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis inhibitors in the treatment of lung cancer.
Shepherd FA
Lung Cancer; 2001 Dec; 34 Suppl 3():S81-9. PubMed ID: 11740999
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
